CN104610195A - 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途 - Google Patents
沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途 Download PDFInfo
- Publication number
- CN104610195A CN104610195A CN201510047703.4A CN201510047703A CN104610195A CN 104610195 A CN104610195 A CN 104610195A CN 201510047703 A CN201510047703 A CN 201510047703A CN 104610195 A CN104610195 A CN 104610195A
- Authority
- CN
- China
- Prior art keywords
- fertile
- ting
- aspartate
- aspartic acid
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 title claims abstract description 93
- 229940009098 aspartate Drugs 0.000 title claims abstract description 64
- 238000002360 preparation method Methods 0.000 title claims abstract description 43
- YQNWZWMKLDQSAC-UHFFFAOYSA-N vortioxetine Chemical compound CC1=CC(C)=CC=C1SC1=CC=CC=C1N1CCNCC1 YQNWZWMKLDQSAC-UHFFFAOYSA-N 0.000 title abstract description 11
- 229960002263 vortioxetine Drugs 0.000 title abstract description 8
- 239000013078 crystal Substances 0.000 claims abstract description 77
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 39
- 235000003704 aspartic acid Nutrition 0.000 claims abstract description 30
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims abstract description 30
- 239000003960 organic solvent Substances 0.000 claims abstract description 21
- 208000024714 major depressive disease Diseases 0.000 claims abstract description 16
- 239000012046 mixed solvent Substances 0.000 claims abstract description 12
- 238000006243 chemical reaction Methods 0.000 claims abstract description 8
- PSWLPHOVWKICMN-JIZZDEOASA-N (2s)-2-aminobutanedioic acid;dihydrate Chemical compound O.O.OC(=O)[C@@H](N)CC(O)=O PSWLPHOVWKICMN-JIZZDEOASA-N 0.000 claims description 32
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 25
- LBXRPPWPQUZKBO-DKWTVANSSA-N (2s)-2-aminobutanedioic acid;hydrate Chemical compound O.OC(=O)[C@@H](N)CC(O)=O LBXRPPWPQUZKBO-DKWTVANSSA-N 0.000 claims description 24
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 24
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 23
- 238000003756 stirring Methods 0.000 claims description 23
- 238000010992 reflux Methods 0.000 claims description 16
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- 239000002904 solvent Substances 0.000 claims description 13
- 238000001291 vacuum drying Methods 0.000 claims description 13
- 238000000967 suction filtration Methods 0.000 claims description 12
- 239000000047 product Substances 0.000 claims description 11
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 8
- 238000009413 insulation Methods 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 7
- 238000005304 joining Methods 0.000 claims description 6
- 238000004458 analytical method Methods 0.000 claims description 5
- 238000002425 crystallisation Methods 0.000 claims description 5
- 230000008025 crystallization Effects 0.000 claims description 5
- 210000004165 myocardium Anatomy 0.000 claims description 5
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 4
- 238000005352 clarification Methods 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 238000004821 distillation Methods 0.000 claims description 4
- 210000004185 liver Anatomy 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 2
- 229940043232 butyl acetate Drugs 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims description 2
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 claims description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 2
- 239000002244 precipitate Substances 0.000 claims description 2
- -1 inorganic acid salt Chemical class 0.000 abstract description 3
- 150000004683 dihydrates Chemical class 0.000 abstract description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 abstract 1
- 238000001816 cooling Methods 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 description 35
- 238000005755 formation reaction Methods 0.000 description 34
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 20
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 238000002441 X-ray diffraction Methods 0.000 description 11
- 230000000694 effects Effects 0.000 description 8
- 238000002411 thermogravimetry Methods 0.000 description 8
- 230000006872 improvement Effects 0.000 description 7
- 238000000113 differential scanning calorimetry Methods 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- 150000003839 salts Chemical group 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 4
- 238000007669 thermal treatment Methods 0.000 description 4
- 239000003513 alkali Substances 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229940076279 serotonin Drugs 0.000 description 3
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940081709 brintellix Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000002050 diffraction method Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- GGRLKHMFMUXIOG-UHFFFAOYSA-M 2-acetyloxyethyl(trimethyl)azanium;hydroxide Chemical compound [OH-].CC(=O)OCC[N+](C)(C)C GGRLKHMFMUXIOG-UHFFFAOYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- CTENFNNZBMHDDG-UHFFFAOYSA-N Dopamine hydrochloride Chemical compound Cl.NCCC1=CC=C(O)C(O)=C1 CTENFNNZBMHDDG-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229940087098 Oxidase inhibitor Drugs 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000005260 alpha ray Effects 0.000 description 1
- 108020004166 alternative oxidase Proteins 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 201000003104 endogenous depression Diseases 0.000 description 1
- 230000005496 eutectics Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-M glutaminate Chemical compound [O-]C(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-M 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 208000011736 mal de Debarquement Diseases 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000010016 myocardial function Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000697 serotonin reuptake Effects 0.000 description 1
- 238000004467 single crystal X-ray diffraction Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 125000004646 sulfenyl group Chemical group S(*)* 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001519 thymoleptic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
Abstract
Description
溶解度(mg/ml) |
沃替西汀游离碱 | 0.1 |
沃替西汀氢溴酸盐β型 | 2.58 |
沃替西汀天冬氨酸盐二水合物 | 18.29 |
沃替西汀天冬氨酸盐无水晶型 | 10.62 |
沃替西汀天冬氨酸盐半水合物 | 17.31 |
增重百分率(%) | |
沃替西汀氢溴酸盐β型 | 0.15 |
沃替西汀甲磺酸盐 | 8 |
沃替西汀天冬氨酸盐二水合物 | 0.13 |
沃替西汀天冬氨酸盐无水晶型 | 4.25 |
沃替西汀天冬氨酸盐半水合物 | 4.82 |
Claims (17)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510047703.4A CN104610195B (zh) | 2015-01-30 | 2015-01-30 | 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510047703.4A CN104610195B (zh) | 2015-01-30 | 2015-01-30 | 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104610195A true CN104610195A (zh) | 2015-05-13 |
CN104610195B CN104610195B (zh) | 2017-06-27 |
Family
ID=53144881
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510047703.4A Active CN104610195B (zh) | 2015-01-30 | 2015-01-30 | 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104610195B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106518807A (zh) * | 2016-09-17 | 2017-03-22 | 北京万全德众医药生物技术有限公司 | 乳酸沃替西汀晶型的制备方法 |
CN108017596A (zh) * | 2018-01-29 | 2018-05-11 | 梧州学院 | 一种沃替西汀和布洛芬新盐型及其制备方法 |
CN116589434A (zh) * | 2023-05-22 | 2023-08-15 | 山东泰合医药科技有限公司 | 一种伏硫西汀昔萘酸盐晶型a及其制备方法与应用 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111330018B (zh) * | 2018-12-18 | 2023-07-21 | 浙江京新药业股份有限公司 | 沃替西汀-环糊精包合物、制备方法及其药物组合物 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1561336A (zh) * | 2001-10-04 | 2005-01-05 | H·隆德贝克有限公司 | 作为血清素再摄取抑制剂的苯基哌嗪衍生物 |
CN101472906A (zh) * | 2006-06-16 | 2009-07-01 | H.隆德贝克有限公司 | 作为用于治疗认知损伤的、具有结合的对血清素再吸收、5-ht3和5-ht1a活性的化合物的1-[2-(2,4-二甲基苯基硫烷基)-苯基]哌嗪 |
CN101636161A (zh) * | 2007-03-20 | 2010-01-27 | H.隆德贝克有限公司 | 1-[2-(2,4-二甲基苯基硫烷基)苯基]哌嗪作为具有结合的5-羟色胺重吸收、5-ht3和5-ht1a活性的化合物用于治疗疼痛或与睡眠和认知有关的抑郁残留症状 |
CN102014908A (zh) * | 2007-11-13 | 2011-04-13 | H.隆德贝克有限公司 | 具有组合的sert、5-ht3和5-ht1a活性的化合物的治疗用途 |
CN102639117A (zh) * | 2009-08-24 | 2012-08-15 | H.隆德贝克有限公司 | 1-[2-(2,4-二甲基-苯基硫基)-苯基]哌嗪的新组合物 |
CN103068389A (zh) * | 2010-08-23 | 2013-04-24 | H.隆德贝克有限公司 | 1-[2-(2,4-二甲基-苯硫基)苯基]哌嗪的治疗用途 |
WO2014090929A1 (en) * | 2012-12-13 | 2014-06-19 | H. Lundbeck A/S | Compositions comprising vortioxetine and donepezil |
-
2015
- 2015-01-30 CN CN201510047703.4A patent/CN104610195B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1561336A (zh) * | 2001-10-04 | 2005-01-05 | H·隆德贝克有限公司 | 作为血清素再摄取抑制剂的苯基哌嗪衍生物 |
CN101472906A (zh) * | 2006-06-16 | 2009-07-01 | H.隆德贝克有限公司 | 作为用于治疗认知损伤的、具有结合的对血清素再吸收、5-ht3和5-ht1a活性的化合物的1-[2-(2,4-二甲基苯基硫烷基)-苯基]哌嗪 |
CN101636161A (zh) * | 2007-03-20 | 2010-01-27 | H.隆德贝克有限公司 | 1-[2-(2,4-二甲基苯基硫烷基)苯基]哌嗪作为具有结合的5-羟色胺重吸收、5-ht3和5-ht1a活性的化合物用于治疗疼痛或与睡眠和认知有关的抑郁残留症状 |
CN102014908A (zh) * | 2007-11-13 | 2011-04-13 | H.隆德贝克有限公司 | 具有组合的sert、5-ht3和5-ht1a活性的化合物的治疗用途 |
CN102639117A (zh) * | 2009-08-24 | 2012-08-15 | H.隆德贝克有限公司 | 1-[2-(2,4-二甲基-苯基硫基)-苯基]哌嗪的新组合物 |
CN103068389A (zh) * | 2010-08-23 | 2013-04-24 | H.隆德贝克有限公司 | 1-[2-(2,4-二甲基-苯硫基)苯基]哌嗪的治疗用途 |
WO2014090929A1 (en) * | 2012-12-13 | 2014-06-19 | H. Lundbeck A/S | Compositions comprising vortioxetine and donepezil |
Non-Patent Citations (1)
Title |
---|
范宁 等: "抗抑郁新药沃替西汀", 《中国新药杂志》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106518807A (zh) * | 2016-09-17 | 2017-03-22 | 北京万全德众医药生物技术有限公司 | 乳酸沃替西汀晶型的制备方法 |
CN108017596A (zh) * | 2018-01-29 | 2018-05-11 | 梧州学院 | 一种沃替西汀和布洛芬新盐型及其制备方法 |
CN116589434A (zh) * | 2023-05-22 | 2023-08-15 | 山东泰合医药科技有限公司 | 一种伏硫西汀昔萘酸盐晶型a及其制备方法与应用 |
Also Published As
Publication number | Publication date |
---|---|
CN104610195B (zh) | 2017-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2014239995B2 (en) | Salt of omecamtiv mecarbil and process for preparing salt | |
JP6526883B2 (ja) | チピラシル塩酸塩の安定形結晶及びその結晶化方法 | |
JP6677739B2 (ja) | ビグアニド化合物及びその使用 | |
JP6189299B2 (ja) | プリドピジン塩酸塩の新規な多形形態 | |
TWI598346B (zh) | Crystallographic polymorphism of 4- [5- (pyridin-4-yl) -1H-1,2,4-triazol-3-yl] pyridine-2-carbonitriles and process for producing the same | |
TWI617554B (zh) | 組織胺h受體之苯并咪唑-2-基嘧啶調控劑 | |
CN103974949B (zh) | 一种酪氨酸激酶抑制剂的二马来酸盐的i型结晶及制备方法 | |
WO2014165090A1 (en) | Compounds for the treatment of tuberculosis | |
CN104610195A (zh) | 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途 | |
JP2015522037A (ja) | ベムラフェニブコリン塩の固体形態 | |
JP6203170B2 (ja) | アゴメラチンの新しい結晶形vii、その調製方法及び使用並びにこれを含有する医薬組成物 | |
JP2016512518A (ja) | ベムラフェニブ塩酸塩の固体形態 | |
US10556896B2 (en) | Crystalline forms of (3-Amino-oxetan-3-ylmethyl)-[2-(5,5-dioxo-5,6,7,9-tetrahydro-5lambda*6*-thia-8-aza-benzocyclohepten-8-yl)-6-methyl-quinazolin-4-yl]-amine | |
CN104628677A (zh) | 一种沃替西汀有机酸盐晶型及其制备方法 | |
US11267791B2 (en) | Highly stable crystalline Eltrombopag monoethanolamine salt form D1 | |
KR20220016949A (ko) | Cdk9 억제제의 결정다형 및 이의 제조방법과 용도 | |
KR20150047134A (ko) | N-[2-({2-[(2S)-2-시아노피롤리딘-1-일]-2-옥소에틸}아미노)-2-메틸프로필]-2-메틸피라졸로[1, 5-a]피리미딘-6-카르복사미드의 결정 | |
US11214547B2 (en) | Crystalline Eltrombopag monoethanolamine salt form D | |
CN105153066B (zh) | 盐酸沃替西汀的结晶型物及其制备方法 | |
CN106478603B (zh) | 尼洛替尼盐酸盐的新晶型及其制备方法和医药用途 | |
KR100857342B1 (ko) | 시부트라민의 신규한 유기산염 및 그의 제조방법 | |
WO2019029477A1 (zh) | 一种酪氨酸激酶抑制剂的二马来酸盐的晶型及其制备方法 | |
BR112016003169B1 (pt) | Polimorfo cristalino de forma 2, composição farmacêutica, uso do polimorfo cristalino de forma 2 e método para a preparação do polimorfo cristalino de forma 2 | |
ITMI20131839A1 (it) | Co-cristallo di un farmaco antidepressivo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 31 Weisan Road, Shangyu Economic and Technological Development Zone, Hangzhou Bay, Shangyu City, Shaoxing City, Zhejiang Province, China, 312369 Patentee after: Shaoxing Jingxin Pharmaceutical Co.,Ltd. Patentee after: ZHEJIANG JINGXIN PHARMACEUTICAL Co.,Ltd. Patentee after: SHANGHAI JINGXIN BIOLOGICAL MEDICAL Co.,Ltd. Address before: 31 Weisan Road, Shangyu Industrial Park, Hangzhou Bay, Shaoxing City, Zhejiang Province, China Patentee before: SHANGYU JINGXIN PHARMACEUTICAL Co.,Ltd. Patentee before: ZHEJIANG JINGXIN PHARMACEUTICAL Co.,Ltd. Patentee before: SHANGHAI JINGXIN BIOLOGICAL MEDICAL Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 312369 No.31, Weisan Road, Shangyu economic and Technological Development Zone, Hangzhou Bay, Shaoxing City, Zhejiang Province Patentee after: Shaoxing Jingxin Pharmaceutical Co.,Ltd. Country or region after: China Patentee after: ZHEJIANG JINGXIN PHARMACEUTICAL Co.,Ltd. Patentee after: SHANGHAI JINGXIN BIOLOGICAL MEDICAL Co.,Ltd. Address before: 31 Weisan Road, Shangyu Economic and Technological Development Zone, Hangzhou Bay, Shangyu City, Shaoxing City, Zhejiang Province, China, 312369 Patentee before: Shaoxing Jingxin Pharmaceutical Co.,Ltd. Country or region before: China Patentee before: ZHEJIANG JINGXIN PHARMACEUTICAL Co.,Ltd. Patentee before: SHANGHAI JINGXIN BIOLOGICAL MEDICAL Co.,Ltd. |